



30th July, 2025

Corporate Relationship Department
M/s. BSE Limited

The Manager - Listing
M/s. National Stock Exchange of India Ltd

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub:- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, we would like to inform you that in accordance with the provisions of Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mr. T.C. Mallikarjun has been appointed as Vice President – QC at Pharma Division, Kothur of the Company w.e.f. 30th July, 2025.

The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024 are as under:

Sl. No.	Particulars	
1	Name	Mr. T.C. Mallikarjun
2	Reason for Change in Senior Management	Appointed as Vice President – QC
3	Date of Appointment & Term of Appointment	30 th July, 2025 & Terms of appointment are as per the Company's Policy
4	Brief profile	Mr. T.C. Mallikarjuna has experience in the leading Indian Pharma Manufacturing Industries. He also has experience in handling regulatory Inspections like USFDA, MHRA, TGA, ANVISA, etc., and managing new products and exhibit validations. He was associated with Aurobindo Pharma Limited, Hyderabad, as Senior General Manager - Head QC before joining the Company.
5	Disclosure of relationship between Directors	Not Applicable

This is for your information and records.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer